Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Jesus Vera-Aguilera"'
Autor:
Nishant Verma, Iman Haji-Abolhassani, Suhas Ganesh, Jesus Vera-Aguilera, Jonas Paludo, Roxana Heitz, Svetomir N. Markovic, Kimary Kulig, Atiyeh Ghoreyshi
Publikováno v:
IEEE Journal of Translational Engineering in Health and Medicine, Vol 9, Pp 1-7 (2021)
Objective: Continuous temperature monitoring in high-risk patients can enable healthcare providers to remotely track patients’ temperatures, promptly detect fevers and timely intervene to improve clinical outcomes. We evaluated if a novel wearable,
Externí odkaz:
https://doaj.org/article/64cca6f7ce5f4a798b33c813b11b1aa4
Autor:
Jesus Vera-Aguilera, MD, Narjust Duma, MD, Kelly Gast, MD, Hassan Alkhateeb, MD, Aaron Tande, MD, Nelson Leung, MD, William J. Hogan, MB ChB, Saad J. Kenderian, MB ChB
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 2, Iss 4, Pp 387-391 (2018)
We report the development of a Shiga toxin–producing Escherichia coli O157 gastrointestinal infection associated with hemolytic uremic syndrome in an allogenic stem cell transplant recipient with a history of gastrointestinal graft-vs-host disease
Externí odkaz:
https://doaj.org/article/8ce4f011f1e149ff92bd6c46573bcafa
Autor:
Riham Suleiman, Patrick McGarrah, Binav Baral, Dawn Owen, Jesus Vera Aguilera, Thor R. Halfdanarson, Katharine A. Price, Harry E. Fuentes Bayne
Publikováno v:
Cancer Reports, Vol 7, Iss 10, Pp n/a-n/a (2024)
ABSTRACT Background Recurrent squamous cell carcinoma (SCC) of the head and neck (SCCHN) remains a formidable clinical challenge despite available treatments. The phosphatidylinositol 3‐kinase (PI3K) pathway has been identified as a potential thera
Externí odkaz:
https://doaj.org/article/2f45e45ef7c3443c86e8549ef1758227
Autor:
Jesus Vera-Aguilera, Hindi Yousef, Diego Beltran-Melgarejo, Teng Hugh Teng, Ramos Jan, Mary Mok, Carlos Vera-Aguilera, Eduardo Moreno-Aguilera
Publikováno v:
Advances in Hematology, Vol 2016 (2016)
Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in
Externí odkaz:
https://doaj.org/article/272d54d360fd4c4ea15fbe54b43b296d
Autor:
Filippo Galli, Jesus Vera Aguilera, Belinda Palermo, Svetomir N. Markovic, Paola Nisticò, Alberto Signore
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-21 (2020)
Abstract Tumor-infiltrating immune cells play a key role against cancer. However, malignant cells are able to evade the immune response and establish a very complex balance in which different immune subtypes may drive tumor progression, metastatizati
Externí odkaz:
https://doaj.org/article/5484d1262ac245a69c4c007a35df75c5
Autor:
Carlos Vera-Aguilera, Jose M. Torres-Zazueta, Jena Konkler, Jesus Vera-Aguilera, Sergio Ariel Soto-Hopkins
Publikováno v:
Open Journal of Anesthesiology. 12:49-54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1567c21aecb4bb9507e711fb5be26469
https://doi.org/10.4236/ojanes.2022.121005
https://doi.org/10.4236/ojanes.2022.121005
Autor:
Jarrett J. Failing, Anagha Bangalore Kumar, Robert R. McWilliams, Svetomir N. Markovic, Roxana S. Dronca, Matthew S. Block, Ying Li, Jonas Paludo, Lisa A. Kottschade, Yiyi Yan, Jesus Vera Aguilera, Henan Zhang, Haidong Dong
Publikováno v:
Melanoma Research
Supplemental Digital Content is available in the text.
Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT
Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a513e0df05dc28790966ff365e4f988
https://pubmed.ncbi.nlm.nih.gov/32404734
https://pubmed.ncbi.nlm.nih.gov/32404734
Autor:
Svetomir N. Markovic, Alberto Signore, Filippo Galli, Belinda Palermo, Jesus Vera Aguilera, Paola Nisticò
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-21 (2020)
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-21 (2020)
Tumor-infiltrating immune cells play a key role against cancer. However, malignant cells are able to evade the immune response and establish a very complex balance in which different immune subtypes may drive tumor progression, metastatization and re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1e85797b04d17733db744d74b27249f
http://europepmc.org/articles/PMC7236372
http://europepmc.org/articles/PMC7236372
Autor:
Miguel Gonzalez Velez, Narjust Duma, Tariq U. Azam, Sejal Kothadia, Joleen M. Hubbard, Ronald S. Go, Thorvardur R. Halfdanarson, Alex A. Adjei, Siddhartha Yadav, Aaron S. Mansfield, Jonas Paludo, Jesus Vera Aguilera, Julian R. Molina
Publikováno v:
The Oncologist. 24:96-102
Background Early phase clinical trials evaluate the safety and efficacy of new treatments. The exclusion/inclusion criteria in these trials are usually rigorous and may exclude many patients seen in clinical practice. Our objective was to study the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eea1388532229ac32d2706ed989799c6
https://doi.org/10.1634/theoncologist.2017-0687
https://doi.org/10.1634/theoncologist.2017-0687
Autor:
Narjust Duma, Saad J. Kenderian, Hassan B. Alkhateeb, Aaron J. Tande, William J. Hogan, Kelly C. Gast, Nelson Leung, Jesus Vera-Aguilera
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 2, Iss 4, Pp 387-391 (2018)
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 2, Iss 4, Pp 387-391 (2018)
We report the development of a Shiga toxin-producing Escherichia coli O157 gastrointestinal infection associated with hemolytic uremic syndrome in an allogenic stem cell transplant recipient with a history of gastrointestinal graft-vs-host disease re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9b1801c33dc447dcabb0570c393a6d0
http://europepmc.org/articles/PMC6260488
http://europepmc.org/articles/PMC6260488